Hari Ramachandra, a savvy investor and analyst, advocates for Sanofi, highlighting its promising pipeline in vaccines and immunology. He addresses potential concerns like patent cliffs while touting Sanofi as a defensive play. Tobias Carlisle, a value investor, passionately pitches Crocs, discussing its attractive valuation, strong free cash flow, and the implications of its Hey Dude acquisition. The hosts also delve into Remitly's competitive edge in digital payments and explore the strategic challenges it faces in expanding its services.
